Here, we establish sarcopenia as a novel parameter identifying a subgroup of patients with an unfavorable prognosis after TACE and propose a score consisting of the psoas muscle index (PMI) and serum albumin concentration for an easy identification of patients that might not benefit from TACE in terms of overall survival. The gene discussed is ALB; the disease is sarcopenia.